Back to News
Market Impact: 0.42
Daiichi Sankyo Gets Japan Approval For Enhertu, Datroway In First-Line Metastatic Breast Cancer
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Japan's Ministry of Health, Labour and Welfare approved Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) for new first-line metastatic breast-cancer indications. The approvals expand the addressable use of two key oncology drugs and should support Daiichi Sankyo's growth outlook in Japan.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
More News
- Google's Gemini becomes latest AI model to break out and hack computer systems
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Google’s Gemini AI hacks 3 companies in security test, then stops
- Analysis-Russia sanctions bill gives Trump sweeping new tariff powers
- India forces caller-ID apps to feed spam reports to telcos
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?